Servatrix Biomed S.L
First in class Therapy for non-alcoholic steatohepatitis and liver fibrosis
Targeting transcription factor NRF2 in chronic diseases
Servatrix research is based on the control of NRF2 degradation.
THE COMPANY
WHO WE ARE?
Servatrix counts with several pipeline candidates that are involved in the homeostatic responses driven by the nuclear factor erythroid 2 – related factor 2 (NRF2). Our vision is to reinforce antioxidant, anti-inflammatory and metabolic responses by modifying pharmacologically the stability of this crucial protein, that participates in multiple homeostatic responses.
THE COMPANY
The heterodimer binds to an enhancer sequence termed Antioxidant Response Element (ARE) that is present in the regulatory regions of genes involved in homeostatic responses associated to relevant liver disease as:
- Regulation of lipid metabolism.
- Protection against oxidative stress.
- Protection against inflammatory stress.
Several proof-of-concept assays have shown unexpected positive results in the NASH area. IP has been protected by Patent filing through the European Patent Office. An extensive regulatory analysis has been carried out and presented. Legal aspects, and possibilities offered by EMA to SMEs for interaction are presented.
Become an investor
JOIN OUR NEXT INVESTMENT ROUND IN Q1 2023
CONTACT US BY EMAIL TO GET:·
– More info about Servatrix Projects
– A confidential sample of Servatrix Investment Deck
– A calendar date to meet our technical team & founders
Servatrix is a biotechnology startup by
Universidad Atónoma de Madrid
